Where does Palvella Therapeutics's income statement data come from?

Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net interest income	$1.07M+106%	$520K-17.2%	$628K-9.0%	$690K-8.2%	$752K+168%
Research and development	$9.33M+31.1%	$7.12M+9.1%	$6.53M+27.5%	$5.12M+25.6%	$4.07M+60.2%
General and administrative	$5.52M+32.0%	$4.18M+14.6%	$3.65M-11.7%	$4.13M+8.8%	$3.8M+108%
Other operating expenses	$14.86M+31.4%	$11.3M+11.1%	$10.18M+10.0%	$9.25M+17.5%	$7.87M+80.3%
Total operating expenses	$14.86M+31.4%	$11.3M+11.1%	$10.18M+10.0%	$9.25M+17.5%	$7.87M+80.3%
Operating income	-$14.86M-31.4%	-$11.3M-11.1%	-$10.18M-10.0%	-$9.25M-17.5%	-$7.87M-80.3%
Other income (expense), net	-$32K—	——	$34K-93.9%	$561K+150%	$224K+22,500%
Income before income taxes	-$15.77M-24.0%	-$12.71M-12.1%	-$11.35M-19.8%	-$9.47M-15.7%	-$8.19M-107%
Income tax expense	$0—	$0—	$0—	$0—	$0—
Net income	-$15.77M-24.0%	-$12.71M-12.1%	-$11.35M-19.8%	-$9.47M-15.7%	-$8.19M-107%
Diluted earnings per share	-$1.20-11.1%	-$1.08-4.9%	-$1.03-19.8%	-$0.86-16.2%	-$0.74—
Basic earnings per share	-$1.20-11.1%	-$1.08-4.9%	-$1.03-19.8%	-$0.86-16.2%	-$0.74—
Weighted-average shares, diluted	13.1M+16.3%	11.3M+1.7%	11.1M+0.1%	11.1M+0.4%	11M+395%
Weighted-average shares, basic	13.1M+16.3%	11.3M+1.7%	11.1M+0.1%	11.1M+0.4%	11M+395%
Fair Value Adjustments On Derivative Liabilities Contingent Value Right Liability	$202K—	——	——	——	$0+100%
Interest Income Expense Nonoperating Royalty Agreement	-$2.04M-17.3%	-$1.74M-15.2%	-$1.51M-11.5%	-$1.35M-11.4%	-$1.22M-8.2%
Other Income Expense From Research And Development Tax Credit Receivable	——	$0—	$0—	$0—	$0-100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$15.76M-23.7%	-$12.74M-14.4%	-$11.13M-16.2%	-$9.58M-16.9%	-$8.19M-143%
Interest Income (Expense), Operating	$1.07M+106%	$520K-17.2%	$628K-9.0%	$690K-8.2%	$752K+168%
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	$8K—	——	$215K+299%	-$108K-1,700%	-$6K-300%
Other income, net (Note 6)	-$32K—	——	$34K-93.9%	$561K+150%	$224K+22,500%
Change in fair value of interest rate swap	-$116K+2.5%	-$119K-45.1%	-$82K+30.5%	-$118K-57.3%	-$75K+67.2%
EBIT	-$14.86M-31.4%	-$11.3M-11.1%	-$10.18M-10.0%	-$9.25M-17.5%	-$7.87M-80.3%
EBITDA	——	——	——	——	——
EBIT	-$14.86M-31.4%	-$11.3M-11.1%	-$10.18M-10.0%	-$9.25M-17.5%	-$7.87M-80.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Palvella Therapeutics's income statement data come from?: Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.